Carboxyamidotriazole Orotate NEW
| Price | $55 | $129 | $197 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-18 |
Product Details
| Product Name: Carboxyamidotriazole Orotate | CAS No.: 187739-60-2 |
| Purity: 99.37% | Supply Ability: 10g |
| Release date: 2024/11/18 |
Product Introduction
Bioactivity
| Name | Carboxyamidotriazole Orotate |
| Description | Carboxyamidotriazole Orotate (L-651582 Orotate) is a cytostatic inhibitor of non-voltage-operated calcium channels and associated signaling pathways. As the orotate salt form of Carboxyamidotriazole (CAI), it is an orally bioavailable signal transduction inhibitor with in vitro antileukaemic activity, exhibiting anti-tumor, anti-inflammatory, and antiangiogenic effects. |
| In vitro | Carboxyamidotriazole Orotate inhibits the phosphorylation of a selected target of Bcr-Abl kinase. Carboxyamidotriazole Orotate (0.1-10 μM; 24-96 hours) inhibits cell proliferation of LAMA84R and K562R cell lines[1]. Tyrosine phosphorylation of CrkL is reduced by 5 μM Carboxyamidotriazole Orotate treatment[1]. |
| In vivo | On CML xenografts, Carboxyamidotriazole Orotate (342, 513 mg/kg; i.p.; Q1D×5 for two rounds) shows antitumor activity[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 5 mg/mL (8.61 mM), Sonication is recommended. |
| Keywords | L651582 | Inhibitor | toxicity | Calcium Channel | L 651582 | Ca2+ channels | Ca channels | leukaemia | inhibit | ovarian | chronic | Carboxyamidotriazole | CAI | Bcr/Abl | L-651582 | cancer | myelogenous | Carboxyamidotriazole Orotate |
| Inhibitors Related | Nisoldipine | Nimodipine | 2,5-Di-tert-butylhydroquinone | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | Lanthanum(III) chloride heptahydrate | Butamben | Ethyl cinnamate | 1-Octanol | 1,2,4-Trihydroxybenzene | Otilonium bromide |
| Related Compound Libraries | 疼痛相關(guān)化合物庫(kù) | 經(jīng)典已知活性庫(kù) | 膜蛋白靶向化合物庫(kù) | 抗癌臨床化合物庫(kù) | 藥物功能重定位化合物庫(kù) | 抑制劑庫(kù) | 神經(jīng)保護(hù)化合物庫(kù) | 已知活性化合物庫(kù) | 離子通道庫(kù) | 抗癌藥物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $468.00/10mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $200.00/1kg |
VIP3Y
|
Hebei Dangtong Import and export Co LTD
|
2024-09-12 | |
| $65.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co.,Ltd
|
2024-05-27 | |
| $55.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-18 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY